PRJNA421286
Gut microbiota of typ2 diabetic patients with hyperlipidemia treated with metformin or Chinese herbal formula
Metabolic diseases such as T2DM and obesity have become worldwide public health threat. Accumulating evidence indicates that gut microbiota can causatively arouse metabolic diseases, thus served as a promising target for diseases control. In this study, we evaluated the role gut microbiota during the improvements of hyperglycemia and hyperlipidemia by two drugs, metformin and a specifically designed Chinese herbal formula (AMC) for diabetic patients with hyperlipidemia. Both drugs significantly ameliorated the symptoms and shifted the gut microbiota. Blautia spp. was identified to be associated with the improvements of glucose and lipid homeostasis for both drugs. AMC exerted larger effects on the gut microbiota together with better efficacies in improving HOMA-IR and plasma triglyceride, which were associated with the enrichment of Faecalibacterium spp.. In brief, these data suggest that gut microbiota might be involved in the alleviation of diabetes with hyperlipidemia by metformin and AMC herbal formula.